Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 22 studies | 34% ± 15% | |
fibroblast | 18 studies | 29% ± 11% | |
astrocyte | 17 studies | 38% ± 18% | |
oligodendrocyte | 15 studies | 40% ± 16% | |
oligodendrocyte precursor cell | 13 studies | 44% ± 19% | |
macrophage | 13 studies | 31% ± 14% | |
pericyte | 12 studies | 27% ± 12% | |
glutamatergic neuron | 11 studies | 45% ± 24% | |
microglial cell | 11 studies | 34% ± 12% | |
mast cell | 11 studies | 26% ± 6% | |
GABAergic neuron | 10 studies | 44% ± 21% | |
adipocyte | 10 studies | 41% ± 10% | |
smooth muscle cell | 9 studies | 26% ± 8% | |
myeloid cell | 7 studies | 29% ± 11% | |
epithelial cell | 7 studies | 38% ± 16% | |
neuron | 6 studies | 43% ± 19% | |
interneuron | 6 studies | 50% ± 24% | |
dendritic cell | 6 studies | 26% ± 6% | |
endothelial cell of lymphatic vessel | 6 studies | 33% ± 11% | |
type I pneumocyte | 6 studies | 33% ± 11% | |
amacrine cell | 5 studies | 22% ± 4% | |
retinal ganglion cell | 5 studies | 25% ± 8% | |
B cell | 5 studies | 23% ± 6% | |
retina horizontal cell | 5 studies | 21% ± 5% | |
cardiac muscle cell | 5 studies | 27% ± 6% | |
ciliated cell | 5 studies | 28% ± 7% | |
lymphocyte | 5 studies | 25% ± 10% | |
basal cell | 5 studies | 30% ± 19% | |
monocyte | 5 studies | 35% ± 8% | |
club cell | 5 studies | 27% ± 8% | |
type II pneumocyte | 5 studies | 29% ± 7% | |
granule cell | 4 studies | 30% ± 7% | |
Mueller cell | 4 studies | 31% ± 6% | |
retinal rod cell | 4 studies | 24% ± 4% | |
T cell | 4 studies | 26% ± 4% | |
myofibroblast cell | 4 studies | 31% ± 12% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 19% ± 2% | |
CD4-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
classical monocyte | 3 studies | 24% ± 7% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
hematopoietic precursor cell | 3 studies | 27% ± 9% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 16% ± 1% | |
non-classical monocyte | 3 studies | 23% ± 7% | |
retinal bipolar neuron | 3 studies | 20% ± 3% | |
GABAergic interneuron | 3 studies | 36% ± 2% | |
glial cell | 3 studies | 31% ± 6% | |
plasma cell | 3 studies | 29% ± 7% | |
mesothelial cell | 3 studies | 27% ± 8% | |
mononuclear phagocyte | 3 studies | 25% ± 6% | |
vein endothelial cell | 3 studies | 28% ± 16% | |
GABAergic amacrine cell | 3 studies | 21% ± 6% | |
glycinergic amacrine cell | 3 studies | 23% ± 3% | |
retinal cone cell | 3 studies | 19% ± 4% | |
endothelial cell of vascular tree | 3 studies | 30% ± 14% | |
hepatocyte | 3 studies | 51% ± 16% | |
retinal pigment epithelial cell | 3 studies | 37% ± 22% | |
natural killer cell | 3 studies | 22% ± 5% | |
connective tissue cell | 3 studies | 28% ± 5% | |
ependymal cell | 3 studies | 52% ± 18% | |
alveolar macrophage | 3 studies | 42% ± 10% | |
goblet cell | 3 studies | 35% ± 22% | |
transit amplifying cell | 3 studies | 36% ± 27% | |
mural cell | 3 studies | 30% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2256.68 | 1445 / 1445 | 100% | 6.81 | 183 / 183 |
brain | 100% | 2056.90 | 2640 / 2642 | 100% | 5.88 | 705 / 705 |
prostate | 100% | 2566.21 | 245 / 245 | 100% | 3.81 | 500 / 502 |
ovary | 100% | 2782.52 | 180 / 180 | 100% | 4.15 | 428 / 430 |
breast | 100% | 2420.42 | 459 / 459 | 99% | 5.02 | 1112 / 1118 |
uterus | 100% | 2727.12 | 170 / 170 | 99% | 4.28 | 456 / 459 |
thymus | 100% | 2776.11 | 653 / 653 | 99% | 4.40 | 601 / 605 |
lung | 100% | 2478.07 | 578 / 578 | 99% | 4.38 | 1147 / 1155 |
bladder | 100% | 2511.71 | 21 / 21 | 98% | 3.46 | 494 / 504 |
pancreas | 100% | 1164.81 | 327 / 328 | 98% | 3.60 | 175 / 178 |
intestine | 100% | 2311.84 | 966 / 966 | 97% | 3.12 | 511 / 527 |
stomach | 100% | 1716.97 | 359 / 359 | 96% | 4.10 | 275 / 286 |
adrenal gland | 100% | 2010.28 | 258 / 258 | 94% | 3.14 | 217 / 230 |
kidney | 100% | 1497.80 | 89 / 89 | 93% | 3.39 | 841 / 901 |
skin | 100% | 2106.97 | 1809 / 1809 | 88% | 3.16 | 417 / 472 |
liver | 100% | 1242.90 | 226 / 226 | 66% | 1.32 | 266 / 406 |
adipose | 100% | 2529.51 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2309.28 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 2303.70 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 3.58 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.24 | 1 / 1 |
muscle | 100% | 1246.55 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 1337.17 | 848 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 2.89 | 27 / 29 |
peripheral blood | 84% | 993.83 | 778 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 51% | 1.16 | 41 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0035196 | Biological process | miRNA processing |
GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
GO_0006402 | Biological process | mRNA catabolic process |
GO_0090625 | Biological process | siRNA-mediated gene silencing by mRNA destabilization |
GO_0035279 | Biological process | miRNA-mediated gene silencing by mRNA destabilization |
GO_0035278 | Biological process | miRNA-mediated gene silencing by inhibition of translation |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0031054 | Biological process | pre-miRNA processing |
GO_0072091 | Biological process | regulation of stem cell proliferation |
GO_0035194 | Biological process | regulatory ncRNA-mediated post-transcriptional gene silencing |
GO_0070922 | Biological process | RISC complex assembly |
GO_0010501 | Biological process | RNA secondary structure unwinding |
GO_0070578 | Cellular component | RISC-loading complex |
GO_0016020 | Cellular component | membrane |
GO_0036464 | Cellular component | cytoplasmic ribonucleoprotein granule |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000932 | Cellular component | P-body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000794 | Cellular component | condensed nuclear chromosome |
GO_0016442 | Cellular component | RISC complex |
GO_0005634 | Cellular component | nucleus |
GO_0004521 | Molecular function | RNA endonuclease activity |
GO_0003727 | Molecular function | single-stranded RNA binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0003723 | Molecular function | RNA binding |
GO_0090624 | Molecular function | endoribonuclease activity, cleaving miRNA-paired mRNA |
GO_0035198 | Molecular function | miRNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0003725 | Molecular function | double-stranded RNA binding |
Gene name | AGO3 |
Protein name | Protein argonaute-3 (Argonaute3) (hAgo3) (EC 3.1.26.n2) (Argonaute RISC catalytic component 3) (Eukaryotic translation initiation factor 2C 3) (eIF-2C 3) (eIF2C 3) Protein argonaute-3 (Argonaute3) (Eukaryotic translation initiation factor 2C 3) (eIF-2C 3) (eIF2C 3) Argonaute RISC catalytic component 3 (Eukaryotic translation initiation factor 2C, 3, isoform CRA_a) Argonaute RISC catalytic component 3 |
Synonyms | hCG_1640521 EIF2C3 |
Description | FUNCTION: Required for RNA-mediated gene silencing (RNAi). Binds to short RNAs such as microRNAs (miRNAs) and represses the translation of mRNAs which are complementary to them. Proposed to be involved in stabilization of small RNA derivates (siRNA) derived from processed RNA polymerase III-transcribed Alu repeats containing a DR2 retinoic acid response element (RARE) in stem cells and in the subsequent siRNA-dependent degradation of a subset of RNA polymerase II-transcribed coding mRNAs by recruiting a mRNA decapping complex involving EDC4. Possesses RNA slicer activity but only on select RNAs bearing 5'- and 3'-flanking sequences to the region of guide-target complementarity . . FUNCTION: Required for RNA-mediated gene silencing (RNAi). Binds to short RNAs such as microRNAs (miRNAs) and represses the translation of mRNAs which are complementary to them. Lacks endonuclease activity and does not appear to cleave target mRNAs. . |
Accessions | ENST00000246314.10 [Q9H9G7-2] ENST00000634486.1 Q9H9G7 ENST00000373191.9 [Q9H9G7-1] ENST00000397828.3 A0A0U1RR19 ENST00000324350.9 A8KA05 Q5TA56 |